MetaStat CEO Oscar L. Bronsther, M.D. to Participate in Moffitt Cancer Center’s 9th Annual Bus. of Biotech Conference in Ta...
2015年4月14日 - 8:30PM
ビジネスワイヤ（英語）
Bronsther to Participate in Panel on Raising
Funds in Biotech
Oscar L. Bronsther, M.D., CEO of MetaStat, Inc. (OTCQB:MTST), a
molecular diagnostic company focused on developing and
commercializing epigenetic-based diagnostic tests for early and
reliable prediction of systemic metastasis, will participate in a
panel discussion at the Moffitt Cancer Center’s 9th Annual Business
of Biotech Conference in Tampa, FL on Friday, April 17.
Dr. Bronsther will be part of the “Raising Funds: What’s
Trending Now” panel, which provides a forum for audience members to
hear the fundraising experiences of successful bioscience
companies. The panel will be held from 1:00 pm to 2:00 pm ET in the
Ferman Conference Room in the Vincent A. Stabile Research Building
at the Moffitt Cancer Center.
The Business of Biotech conference is designed to give
biomedical companies, startups, service providers, entrepreneurs
and investors a range of insights about collaborating through
successful partnerships. More information on the conference can be
found at the following link:
http://www.cvent.com/events/moffitt-cancer-center-s-9th-annual-business-of-biotech-conference/event-summary-8439872d1915408583b36d59a2725891.aspx?ct=8703c9f0-2652-4554-96a2-5bce199b6b4f
About MetaStat, Inc.
MetaStat, Inc. (MTST) is a molecular diagnostic company that
develops and commercializes diagnostic tests for early and reliable
prediction of systemic metastasis, the process by which cancer
spreads from a primary tumor through the bloodstream to other areas
of the body. MetaStat is focused on breast, prostate, lung and
colorectal cancers, where systemic metastasis is responsible for
approximately 90% of all deaths. The company’s function-based
diagnostic platform technology is based on the identification and
understanding of the pivotal role of the mena protein and its
isoforms, a common pathway for the development of systemic
metastatic disease in all epithelial-based solid tumors. Both the
MetaSite Breast™ and MenaCalc™ assays are designed to accurately
stratify patients based on their individual risk of metastasis and
to provide physicians with clinically actionable information to
better "customize" cancer treatment. MetaStat’s testing platform
improves treatment planning decisions by positively identifying
patients with a high-risk of metastasis who need aggressive therapy
and by sparing patients with a low-risk of metastasis from the
harmful side effects and expense of chemotherapy. The company is
based in Boston.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of
various factors and other risks, including those set forth in the
company's Form 10-K filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and the company undertakes
no obligation to update such statements.
Media:Dian Griesel Int’l. for MetaStatSusan Forman,
212-825-3210sforman@dgicomm.comorInvestors:MetaStat, Inc.Douglas
Hamilton, 917-597-4164Dhamilton@metastat.com
MetaStat (CE) (USOTC:MTST)
過去 株価チャート
から 10 2024 まで 11 2024
MetaStat (CE) (USOTC:MTST)
過去 株価チャート
から 11 2023 まで 11 2024
